Defining a molecular phenotype for benign and malignant parathyroid tumors

Cancer

Volumn 115, Issue 2, 2009, Pages 334-344

  Fernandez Ranvier, Gustavo G ^a   Khanafshar, Elham ^b   Tacha, David ^c   Wong, Mariwil ^a   Kebebew, Electron ^a   Duh, Quan Yang ^a   Clark, Orlo H ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Biocare Medical   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atypical parathyroid adenoma; Cell cycle regulators; Hyperparathyroidism; Immunohistochemistry; Parathyroid carcinoma; Parathyroid tumor biomarkers; Parathyroid tumors; Parathyromatosis; Tumor suppressor genes

Indexed keywords

GALECTIN 3; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P27; RETINOBLASTOMA PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID TUMOR; PARATHYROMATOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH;

ADENOMA; CARCINOMA; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PARATHYROID DISEASES; PARATHYROID NEOPLASMS; PHENOTYPE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 59449099285     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24037     Document Type: Article

References (35)

1. Lal G, Clark OH. Primary hyperparathyroidism: controversies in surgical management. Trends Endocrinol Metab. 2003;14:417-422.
2. Clark OH. How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab. 2003;88:3011-3014.
3. Boger MS, Perrier ND. Benign primary tumors: primary hyperparathyroidism. In: Clark OH, Duh QY, Perrier ND, Kebebew, E, eds. Endocrine Tumors. Hamilton, Ontario, Canada: BC Decker; 2003:58-73.
4. Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. Cancer. 1999;86:538-544.
5. Takami H, Kameyama K, Nagakubo I. Parathyroid carcinoma in a patient receiving long-term hemodialysis. Surgery. 1999;125:239-240.
6. Palmer JA, Brown WA, Kerr WH, et al. The surgical aspects of hyperparathyroidism. Arch Surg. 1975;110:1004-1007.
7. Rattner DW, Marrone GC, Kasdon E, et al. Recurrent hy-perparathyroidism due to implantation of parathyroid tissue. Am J Surg. 1985;149:745-748.
8. Kollmorgen CF, Aust MR, Ferreiro JA, et al. Parathyromatosis: a rare yet important cause of persistent or recurrent hyperparathyroidism. Surgery. 1994;116:111-115.
9. Lee PC, Mateo RB, Clarke MR, et al. Parathyromatosis: a cause for recurrent hyperparathyroidism. Endocr Pract. 2001;7:189-192.
10. Reddick RL, Costa JC, Marx SJ. Parathyroid hyperplasia and parathyromatosis. Lancet. 1977;1:549.
11. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
12. Cryns VL, Rubio MP, Thor AD, et al. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 1994;78:1320-1324.
13. Haines DS, Landers JE, Engle LJ, et al. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol. 1994;14:1171-1178.
14. Miwa S, Uchida C, Kitagawa K, et al. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53- independent manner. Biochem Biophys Res Commun. 2006;340:54-61.
15. Erickson LA, Jin L, Wollan P, et al. Parathyroid hyper-plasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol. 1999;23:288-295.
16. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblas-toma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757-761.
17. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf). 1996;45:195-200.
18. Dotzenrath C, Teh BT, Farnebo F, et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab. 1996;81:3194-3196.
19. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf). 2004;60:99-106.
20. Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohisto-chemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol. 1995;6:279-287.
21. Bergero N, De Pompa R, Sacerdote C, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol. 2005;36:908-914.
22. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis. 2005;10:267-275.
23. Saggiorato E, Bergero N, Volante M, et al. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol. 2006;126:59-66.
24. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676-680.
25. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
26. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40:657-663. Erratum in: J Med Genet. 2004;41:20.
27. Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255-264.
28. Cetani F, Ambrogini E, Viacava P, et al. Should parafibro-min staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007;156:547-554.
29. Sanabria A, Carvalho AL, Piana de Andrade V, et al. Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of ''follicular neoplasm''? A critical appraisal of the evidence. Head Neck. 2007;29:1046-1054.
30. Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89:5583-5591.
31. Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30: 1140-1149.
32. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629-6637.
33. Juhlin C, Larsson C, Yakoleva T, et al. Loss of parafibro-min expression in a subset of parathyroid adenomas. Endocr Relat Cancer. 2006;13:509-523.
34. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. Clin Endocrinol Metab. 2005;90:5015-5017.
35. Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer. 2007;14:501-512.